Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1719595

	registered interest
	date	21/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bladder Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number of people that have been (a) diagnosed with and (b) treated for bladder cancer in the last 12 months.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	27369
	answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>Whilst the Department will not make a specific estimate, the following link shows the number of diagnoses of bladder cancer in England for 2019 and 2020, the most recent years for which NHS Digital holds publicly available data:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2020/cancer-diagnoses-in-2020" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2020/cancer-diagnoses-in-2020</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 11:30:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1719343

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	UK Biobank: Ethnic Groups
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) UK Biobank and (b) UK Biobank funders on the adequacy of the proportion of UK Biobank participants from BAME backgrounds.
	tabling member constituency	Walsall South
	tabling member printed	Valerie Vaz
	uin	27024
	answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>The scientific and ethical impacts of cohort diversity on the generalisability of research findings is part of ongoing conversations on health data, including with UK Biobank. As a funder, the Government routinely engages in discussions about diversity with UK Biobank through the Medical Research Council and National Institute for Health and Care Research. The Department is committed to increasing participation of ethnic minority groups in health and social care research, and is working in partnership with diverse communities to ensure they have a stronger voice in shaping priorities for research, the design and delivery of research, inclusive recruitment into studies, and the mobilisation of evidence into practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 13:29:24 answering member 4044 label Biography information for Andrew Stephenson previous answer version 36821 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4076 label Biography information for Valerie Vaz

1719342

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	South Asia Bio Bank: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will have discussions with (a) the National Institute for Health Research and (b) other NHS funding streams on the potential merits of increasing the level of funding made available to the South Asian Biobank to help monitor (i) disease diagnoses and (ii) health outcomes from that project among people from South Asian backgrounds.
	tabling member constituency	Walsall South
	tabling member printed	Valerie Vaz
	uin	27023
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The South Asian Biobank, originally funded by the Wellcome Trust, is an international research study designed to prevent the high risk of cardiovascular disease, diabetes, and cancer among South Asian people. The National Institute for Health and Care Research (NIHR) funds research via a range of programmes, with eligibility criteria to support applicants to decide where to apply. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR has provided funding for research projects associated with the South Asian Biobank through open competition, and welcomes any future applications. In addition, the NIHR provides funding to NIHR research infrastructure through open competition. The NIHR Imperial Biomedical Research Centre and the Clinical Research Network have provided support for the South Asian Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 27025 question first answered 23/05/2024 07:42:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4076 label Biography information for Valerie Vaz

1719345

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	South Asia Bio Bank: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of increasing the level of funding allocated to the South Asian Biobank.
	tabling member constituency	Walsall South
	tabling member printed	Valerie Vaz
	uin	27025
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The South Asian Biobank, originally funded by the Wellcome Trust, is an international research study designed to prevent the high risk of cardiovascular disease, diabetes, and cancer among South Asian people. The National Institute for Health and Care Research (NIHR) funds research via a range of programmes, with eligibility criteria to support applicants to decide where to apply. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR has provided funding for research projects associated with the South Asian Biobank through open competition, and welcomes any future applications. In addition, the NIHR provides funding to NIHR research infrastructure through open competition. The NIHR Imperial Biomedical Research Centre and the Clinical Research Network have provided support for the South Asian Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 27023 question first answered 23/05/2024 07:42:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4076 label Biography information for Valerie Vaz

1719292

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prince's Trust: Contracts
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Minister without Portfolio's article of 12 May 2024 in The Sunday Telegraph, when her Department is expected to terminate its contract with the Prince's Trust, order reference C191156; and whether a notice period is required under the provisions of clause 10.2.2 of that contract.
	tabling member constituency	Islington South and Finsbury
	tabling member printed	Emily Thornberry
	uin	26990
	answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 14:03:28 answering member 4044 label Biography information for Andrew Stephenson previous answer version 36822 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1536 label Biography information for Emily Thornberry

1719284

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pancreatic Enzyme Replacement Therapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of access to (a) Creon and (b) other drugs that contain pancreatic enzymes for patients after pancreatic surgery.
	tabling member constituency	Broxbourne
	tabling member printed	Sir Charles Walker
	uin	26982
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10,000 gastro-resistant capsules; Creon 25,000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 15:24:29 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1493 label Biography information for Sir Charles Walker

1719437

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that Liothyronine is acquired by the NHS at the best possible price.
	tabling member constituency	Portsmouth South
	tabling member printed	Stephen Morgan
	uin	27175
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>Liothyronine is marketed as a generic medicine. For generic medicines, we rely on competition to keep prices down. This works well for the most part, as evidence shows we have amongst the lowest prices in Europe for generic medicines. The system also means we have a relatively resilient supply, as flexibility on pricing allows manufacturers to increase prices where supply on a particular drug is reduced or demand increases, supporting continuity of supply for patients in the United Kingdom.</p><p>Between 2009 and 2017, there was only one supplier of liothyronine, and they were charging a price considered to be excessive and unfair by the Competition and Markets Authority (CMA). Following an investigation which concluded in July 2021, the CMA decided to issue fines totalling £101.4 million against the three undertakings which controlled the supply during this time.</p><p>That decision is currently under appeal before the Court of Appeal, having previously been upheld by the Competition Appeal Tribunal in August 2023. Since 2016, several marketing authorisations have been granted to other suppliers for liothyronine, and its price to the National Health Service has been decreasing as a result of direct competition in the market. The Department has no price comparison information on liothyronine.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 27176 question first answered 23/05/2024 16:45:16 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4653 label Biography information for Stephen Morgan

1719438

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a comparative estimate of the cost of Liothyronine in (a) the UK and (b) other countries.
	tabling member constituency	Portsmouth South
	tabling member printed	Stephen Morgan
	uin	27176
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>Liothyronine is marketed as a generic medicine. For generic medicines, we rely on competition to keep prices down. This works well for the most part, as evidence shows we have amongst the lowest prices in Europe for generic medicines. The system also means we have a relatively resilient supply, as flexibility on pricing allows manufacturers to increase prices where supply on a particular drug is reduced or demand increases, supporting continuity of supply for patients in the United Kingdom.</p><p>Between 2009 and 2017, there was only one supplier of liothyronine, and they were charging a price considered to be excessive and unfair by the Competition and Markets Authority (CMA). Following an investigation which concluded in July 2021, the CMA decided to issue fines totalling £101.4 million against the three undertakings which controlled the supply during this time.</p><p>That decision is currently under appeal before the Court of Appeal, having previously been upheld by the Competition Appeal Tribunal in August 2023. Since 2016, several marketing authorisations have been granted to other suppliers for liothyronine, and its price to the National Health Service has been decreasing as a result of direct competition in the market. The Department has no price comparison information on liothyronine.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 27175 question first answered 23/05/2024 16:45:16 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4653 label Biography information for Stephen Morgan

1719369

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services and Social Services: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number of children that have lost their place on waiting lists for health and care services as a result of relocating out of area due to housing pressures, in the latest period for which data is available.
	tabling member constituency	Salford and Eccles
	tabling member printed	Rebecca Long Bailey
	uin	27056
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>It is important that the correct start date is captured for patients who transfer from a referral to treatment (RTT) pathway between providers. For patients that move between different areas of England and transfer to a new provider, including children who may relocate out of an area due to housing pressures, there is an established Inter Provider Transfer process which ensures that the patient is transferred with the same RTT clock start date, so that the new provider considers the amount of time the patient has already waited. This is detailed in Section 11.3 of NHS England’s Recording and reporting RTT waiting times for consultant-led elective care guidance, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2024/02/Recording-and-reporting-referral-to-treatment-RTT-waiting-times-for-consultant-led-elective-care-v4-1.pdf" target="_blank">https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2024/02/Recording-and-reporting-referral-to-treatment-RTT-waiting-times-for-consultant-led-elective-care-v4-1.pdf</a></p><p>Data on the number of children that have lost their place on waiting lists for health and care services as a result of relocating out of area due to housing pressures is not collected, therefore no estimate has been made.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 16:39:26 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4396 label Biography information for Rebecca Long Bailey

1719200

	registered interest
	date	20/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Licensing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what flexibility (a) NICE and (b) NHS England have to approve for use drugs that (i) are used in combination with other drugs, (ii) are used for various (A) conditions and (B) lines of treatment and (iii) provide significant benefits for some but not all patients; and what tools those organisations use to ensure the effectiveness of such appraisals.
	tabling member constituency	Birmingham, Yardley
	tabling member printed	Jess Phillips
	uin	27051
	answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines, and significant licence extensions for existing medicines, should be routinely funded by the NHS. The NICE is able to recommend most new medicines for use by the NHS, including as a result of commercial agreements negotiated between NHS England and the company, in line with the commercial framework for new medicines.</p><p>The NICE develops its guidance in line with its published health technology evaluations manual, which sets out the circumstances in which its Appraisal Committees are able to apply flexibility in the evaluation of specific treatments. The NICE is, for example, able to apply a modifier in the evaluation of medicines for severe diseases that means that its committees are able to recommend medicines at a higher cost-effectiveness threshold than for less severe diseases. The NICE appraises combination therapies using the same methods that it uses for appraising single drug therapies.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 16:08:56 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4370 label Biography information for Jess Phillips